Pure Biologics Balance Sheet Health
Financial Health criteria checks 4/6
Pure Biologics has a total shareholder equity of PLN13.0M and total debt of PLN12.3M, which brings its debt-to-equity ratio to 94.7%. Its total assets and total liabilities are PLN65.2M and PLN52.2M respectively.
Key information
94.7%
Debt to equity ratio
zł12.33m
Debt
| Interest coverage ratio | n/a |
| Cash | zł10.62m |
| Equity | zł13.02m |
| Total liabilities | zł52.16m |
| Total assets | zł65.18m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PQB's short term assets (PLN30.3M) exceed its short term liabilities (PLN13.7M).
Long Term Liabilities: PQB's short term assets (PLN30.3M) do not cover its long term liabilities (PLN38.4M).
Debt to Equity History and Analysis
Debt Level: PQB's net debt to equity ratio (13.1%) is considered satisfactory.
Reducing Debt: PQB's debt to equity ratio has increased from 3.4% to 94.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PQB has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: PQB is forecast to have sufficient cash runway for 5 months based on free cash flow estimates, but has since raised additional capital.